Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto

dc.contributor.author	Ibáñez, Sebastián
dc.contributor.author	Valenzuela, Francisca
dc.contributor.author	Valenzuela, Omar
dc.date.accessioned	2021-08-24T15:51:41Z
dc.date.available	2021-08-24T15:51:41Z
dc.date.issued	2020
dc.description.abstract	The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.	es
dc.identifier.citation	Revista Médica de Chile, 2020, vol.148: 657-664	es
dc.identifier.uri	https://dx.doi.org/10.4067/S0034-98872020000500657	es
dc.identifier.uri	http://hdl.handle.net/11447/4442
dc.language.iso	es	es
dc.subject	Arthritis	es
dc.subject	Psoriatic	es
dc.subject	Biological Therapy	es
dc.subject	Spondylitis	es
dc.subject	Ankylosing	es
dc.title	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto	es
dc.title.alternative	Choosing biological agents for the treatment of psoriatic arthritis	es
dc.type	Article	es

Files

Now showing 1 - 1 of 1

Name:: Choosing biological agents for the treatment of psoriatic arthritis.pdf
Size:: 659.01 KB
Format:: Adobe Portable Document Format
Description:: Texto completo

Now showing 1 - 1 of 1